Literature DB >> 32272500

Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials.

Salvatore Corallo1, Giovanni Fucà1, Federica Morano1, Massimiliano Salati2, Andrea Spallanzani2, Annunziata Gloghini3, Chiara Costanza Volpi3, Desirè Viola Trupia3, Riccardo Lobefaro1, Vincenzo Guarini1, Massimo Milione3, Laura Cattaneo3, Maria Antista1, Michele Prisciandaro1, Alessandra Raimondi1, Carlo Sposito4, Vincenzo Mazzaferro4,5, Filippo de Braud1,5, Filippo Pietrantonio1,5, Maria Di Bartolomeo1.   

Abstract

BACKGROUND: Epstein-Barr virus (EBV)-positive gastric cancers (GCs) have been recently identified as a molecular subgroup showing excellent outcomes after surgery for early-stage disease and responsiveness to immune checkpoint inhibitors (ICIs) for metastatic stage. No data are available on the prevalence, clinical characteristics, and prognosis of this subgroup of GCs in the metastatic setting.
MATERIALS AND METHODS: In this cohort study, we assessed the impact of EBV status in patients with metastatic GC treated with chemotherapy at two Italian institutions.
RESULTS: Among the 175 cases analyzed, only 7 (4%) were EBV positive and all showed long-lasting and even complete responses to first-line chemotherapy with fluorouracil and platinum and a significantly better survival compared with EBV-negative patients (3-year overall survival: 80% vs. 20.1%; hazard ratio: 0.12).
CONCLUSION: If confirmed in larger data sets, our results may give a strong rationale for investigating the addition of ICIs to chemotherapy, in order to maximize the chance of achieving durable and complete responses in this uncommon subtype of GC. IMPLICATIONS FOR PRACTICE: To date, no data are available on the prevalence and clinical characteristics of patients with Epstein-Barr virus (EBV)-positive metastatic gastric cancer (GC), a specific subtype of GC showing excellent outcomes after radical surgery in early-stage disease and responsiveness to immune checkpoint inhibitors (ICIs). This cohort study showed that patients with EBV-positive GC who did not receive ICIs had exceptional, long-lasting, and even complete responses to first-line chemotherapy with fluorouracil and platinum and a significantly better survival compared with EBV-negative patients. If confirmed in larger series, these results may give a strong rationale for investigating the combination of chemotherapy and ICIs to achieve durable and potentially complete response in this uncommon subtype of GC. © AlphaMed Press 2020.

Entities:  

Keywords:  Epstein-Barr virus infection; Gastric cancer; Molecular classification

Mesh：

Year:  2020        PMID： 32272500      PMCID： PMC7485344          DOI： 10.1634/theoncologist.2020-0037

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  15 in total

1.  Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.

Authors:  Maria Di Bartolomeo; Federica Morano; Alessandra Raimondi; Rosalba Miceli; Salvatore Corallo; Elena Tamborini; Federica Perrone; Maria Antista; Monica Niger; Alessandro Pellegrinelli; Giovanni Randon; Filippo Pagani; Antonia Martinetti; Giovanni Fucà; Filippo Pietrantonio
Journal:  Oncologist       Date:  2019-11-25

2.  Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.

Authors:  Filippo Pietrantonio; Rosalba Miceli; Alessandra Raimondi; Young Woo Kim; Won Ki Kang; Ruth E Langley; Yoon Young Choi; Kyoung-Mee Kim; Matthew Guy Nankivell; Federica Morano; Andrew Wotherspoon; Nicola Valeri; Myeong-Cherl Kook; Ji Yeong An; Heike I Grabsch; Giovanni Fucà; Sung Hoon Noh; Tae Sung Sohn; Sung Kim; Maria Di Bartolomeo; David Cunningham; Jeeyun Lee; Jae-Ho Cheong; Elizabeth Catherine Smyth
Journal:  J Clin Oncol       Date:  2019-09-12       Impact factor: 44.544

3.  Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).

Authors:  J Goldstein; B Tran; J Ensor; P Gibbs; H L Wong; S F Wong; E Vilar; J Tie; R Broaddus; S Kopetz; J Desai; M J Overman
Journal:  Ann Oncol       Date:  2014-02-27       Impact factor: 32.976

4.  Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.

Authors:  Yoon Young Choi; Hyunki Kim; Su-Jin Shin; Ha Yan Kim; Jinae Lee; Han-Kwang Yang; Woo Ho Kim; Young-Woo Kim; Myeong-Cherl Kook; Young Kyu Park; Hyung-Ho Kim; Hye Seung Lee; Kyung Hee Lee; Mi Jin Gu; Seung Ho Choi; SoonWon Hong; Jong Won Kim; Woo Jin Hyung; Sung Hoon Noh; Jae-Ho Cheong
Journal:  Ann Surg       Date:  2019-08       Impact factor: 12.969

5.  A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits.

Authors:  Simona Corso; Claudio Isella; Sara E Bellomo; Maria Apicella; Stefania Durando; Cristina Migliore; Stefano Ughetto; Laura D'Errico; Silvia Menegon; Daniel Moya-Rull; Marilisa Cargnelutti; Tânia Capelôa; Daniela Conticelli; Jessica Giordano; Tiziana Venesio; Antonella Balsamo; Caterina Marchiò; Maurizio Degiuli; Rossella Reddavid; Uberto Fumagalli; Stefano De Pascale; Giovanni Sgroi; Emanuele Rausa; Gian Luca Baiocchi; Sarah Molfino; Filippo Pietrantonio; Federica Morano; Salvatore Siena; Andrea Sartore-Bianchi; Maria Bencivenga; Valentina Mengardo; Riccardo Rosati; Daniele Marrelli; Paolo Morgagni; Stefano Rausei; Giovanni Pallabazzer; Michele De Simone; Dario Ribero; Silvia Marsoni; Antonino Sottile; Enzo Medico; Paola Cassoni; Anna Sapino; Eirini Pectasides; Aaron R Thorner; Anwesha Nag; Samantha D Drinan; Bruce M Wollison; Adam J Bass; Silvia Giordano
Journal:  Cancer Res       Date:  2019-10-04       Impact factor: 12.701

6.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.

Authors:  Seung Tae Kim; Razvan Cristescu; Adam J Bass; Kyoung-Mee Kim; Justin I Odegaard; Kyung Kim; Xiao Qiao Liu; Xinwei Sher; Hun Jung; Mijin Lee; Sujin Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Hyuk Lee; Mingew Choi; AmirAli Talasaz; Peter Soonmo Kang; Jonathan Cheng; Andrey Loboda; Jeeyun Lee; Won Ki Kang
Journal:  Nat Med       Date:  2018-07-16       Impact factor: 53.440

7.  Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.

Authors:  Sabine Venderbosch; Iris D Nagtegaal; Tim S Maughan; Christopher G Smith; Jeremy P Cheadle; David Fisher; Richard Kaplan; Philip Quirke; Matthew T Seymour; Susan D Richman; Gerrit A Meijer; Bauke Ylstra; Danielle A M Heideman; Anton F J de Haan; Cornelis J A Punt; Miriam Koopman
Journal:  Clin Cancer Res       Date:  2014-08-19       Impact factor: 12.531

8.  Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.

Authors:  Elizabeth C Smyth; Andrew Wotherspoon; Clare Peckitt; David Gonzalez; Sanna Hulkki-Wilson; Zakaria Eltahir; Matteo Fassan; Massimo Rugge; Nicola Valeri; Alicia Okines; Madeleine Hewish; William Allum; Sally Stenning; Matthew Nankivell; Ruth Langley; David Cunningham
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 33.006

9.  Comprehensive molecular characterization of gastric adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

10.  Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial.

Authors:  Chul Kyu Roh; Yoon Young Choi; Seohee Choi; Won Jun Seo; Minah Cho; Eunji Jang; Taeil Son; Hyoung Il Kim; Hyeseon Kim; Woo Jin Hyung; Yong Min Huh; Sung Hoon Noh; Jae Ho Cheong
Journal:  Yonsei Med J       Date:  2019-02       Impact factor: 2.759
View more
  5 in total

1.  Clinicopathological and Immunomicroenvironment Characteristics of Epstein-Barr Virus-Associated Gastric Cancer in a Chinese Population.

Authors:  Xiaoxia Jia; Ting Guo; Zhemin Li; Meng Zhang; Yi Feng; Bin Dong; Zhongwu Li; Ying Hu; Ziyu Li; Xiaofang Xing; Shuqin Jia; Jiafu Ji
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

Review 2.  Overview of Epstein-Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic Options.

Authors:  Valli De Re; Giulia Brisotto; Ombretta Repetto; Mariangela De Zorzi; Laura Caggiari; Stefania Zanussi; Lara Alessandrini; Vincenzo Canzonieri; Gianmaria Miolo; Fabio Puglisi; Claudio Belluco; Agostino Steffan; Renato Cannizzaro
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

3.  Clinicopathological Characteristics and Response to Chemotherapy in Treatment-Naive Epstein-Barr Virus Associated Gastric Cancer: A Retrospective Study.

Authors:  Tong Xie; Zhi Peng; Yiqiang Liu; Zhening Zhang; Xiaotian Zhang; Jian Li; Ming Lu; Jifang Gong; Changsong Qi; Jiafu Ji; Lin Shen
Journal:  Front Oncol       Date:  2021-09-23       Impact factor: 6.244

4.  Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving Immunotherapy.

Authors:  Fangli Jiang; Zhening Zhang; Xiaoyi Chong; Lin Shen; Meng Fan; Xuan Liu; Jin An; Zhi Peng; Cheng Zhang
Journal:  Cancers (Basel)       Date:  2022-08-28       Impact factor: 6.575

Review 5.  The Roles of the Virome in Cancer.

Authors:  Felix Broecker; Karin Moelling
Journal:  Microorganisms       Date:  2021-12-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.